Skip to content
ESPT
MARKETS / NASDAQ / Health care / Medicinal chemicals / BON
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Bon Natural Life Ltd. BON

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$18.7M
▼ 21.7% YoY
$-2.0M
▼ 601.0% YoY
$134,288

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We commenced our natural products and ingredients business through Xi’an App-Chem Bio(Tech) Co., Ltd. (“Xi’an App-Chem”), a corporation formed in the People’s Republic of China in April of 2006. On June 28, 2021, the Company closed its initial public offering (“IPO”) of 8,800 ordinary shares, par value US$0.025 per share at a public offering price of $1,250 per share, and the Company’s ordinary shares started to trade on the Nasdaq Capital Market under the ticker symbol “BON” since June 24, 2021. We were co-founded by a team of top-level executives from China’s domestic natural products industry, together with experts returned from overseas. All of our actual business operations in China are conducted through Xi’an App-Chem and its subsidiaries.

Written from the business description in Bon Natural Life Ltd's annual report to the U.S. Securities and Exchange Commission, filed 23 January 2026. Every sentence was checked against that document before publication.

Growth

USD 18.7M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 18.7 · Net income -2.0
15M30M
201920222025
Compound annual growth
−14.5%
+0.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−11 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -8.7% · Net -11.0%
10%20%-5%-10%
201920222025
ROE
FY2025 · ROE -3.9%
10%20%30%
201920222025
Three returns, three denominators.
Gross margin20.8%
Operating margin-8.7%
Net margin-11.0%
EBITDAUSD -574,329.00

Each USD of equity lost 4 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.1
2.5M5.0M-3.0M-6.0M
201920222025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 85.2M
EquityUSD 57.6M
CashUSD 6.3M
Gross debtUSD 1.9M
Net debtUSD -4.3M
Current ratio1.74×

The company holds more cash than debt.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BON, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.00.00.00.00.00.00.0
EBITDA $B−0.00.00.00.00.00.00.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B−0.00.00.00.00.00.00.0
Free cash flow $B0.0−0.0−0.0−0.00.00.00.0
EPS, diluted $−0.724.14124.927.430.680.580.50
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−3.91.014.122.425.134.035.4
Shares out B◌0.000.010.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsSeptember 30
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image